Industries de la santé

Growing Bone from Stem Cells in Fat Could End Painful Graft Operations

Imprimer PDF

Écrit par STEM CELLS Translational Medicine | 11 Juin 2012

Durham, NC – Bone grafts grown from purified stem cells originating from fat could lead to a more efficient way to regenerate bone and end the painful operations needed to collect a patient’s own bone for grafting. The results could have significant impact on those suffering from severe bone injuries or disease. 

In a study published in the June issue of STEM CELLS Translational...

Lire la suite... Ajouter un commentaire

Sanofi Looks to Amylin to Expand its Diabetes Portfolio

Imprimer PDF

Écrit par GlobalData | 08 Juin 2012

LONDON, UK (GlobalData), 7 June 2012 - The head of global research and development (R&D) for Sanofi, Elias Zerhouni, stated on May 31 that the company intends to expand its presence in the diabetes market space. Currently, Sanofi markets Lantus (injectable insulin glargine from rDNA origin), and will likely be filing for a new drug application (NDA) of its once-daily GLP-1 receptor...

Lire la suite... Ajouter un commentaire

VEXIM étoffe son équipe de Direction Nomination de Marie-Pierre Hontas au poste de Directrice des Affaires Cliniques de Vexim

Imprimer PDF

Écrit par Vexim | 06 Juin 2012

Toulouse, le 6 juin 2012 - Vexim (FR0011072602 ALVXM), société Med-Tech spécialisée dans la restauration anatomique mini invasive des fractures vertébrales, annonce la nomination de Marie-Pierre Hontas au poste de Directrice des Affaires Cliniques. Marie-Pierre Hontas dispose de 20 années d'expérience en recherche clinique internationale acquise dans l'industrie pharmaceutique et le...

Lire la suite... Ajouter un commentaire

FDA Bill Passes House and Senate: Amendment on Imported Drugs Defeated - Large Contributions from PhRMA & Healthcare Industry to Both Chambers

Imprimer PDF

Écrit par MapLight | 04 Juin 2012

The U.S. House of Representatives passed its version of the FDA user fee bill ( H.R. 5651) Wednesday 387-5. The vote comes on the heels of the Senate’s 96-1 vote passing their version of the bill ( S. 3187) last week. The different bills would need to be reconciled in a conference committee and receive approval from both chambers before receiving President Obama's signature.

Given...

Lire la suite... Ajouter un commentaire

Bacteria Builds Up as Pharmaceutical Progress Lags

Imprimer PDF

Écrit par GBI Research | 29 Mai 2012

NEW YORK (GBI Research), 29 May 2012 - Drug resistance and patent expiries are demanding that the antibacterial drug market moves forwards soon, but a current lack of interest from pharmaceutical companies has led to market stagnation, according to a new report by healthcare experts GBI Research.

The new report* shows that while hospital hygiene campaigns to conquer MRSA encourage...

Lire la suite... Ajouter un commentaire

Clinical Oncology Summit Approaches, Anticipation Mounts!

Imprimer PDF

Écrit par GlobalData | 18 Mai 2012

LONDON, UK (GlobalData), 18 May 2012 - The upcoming American Society of Clinical Oncology (ASCO) meeting is one of the most highly anticipated events in the world of cancer pharmaceuticals. This year’s 48th annual meeting will be held in Chicago from June 1-5, and investors and media outlets are already buzzing. The meeting abstracts released by ASCO on Wednesday, May 16 represent a...

Lire la suite... Ajouter un commentaire

DBV Technologies : Chiffre d'affaires du 1er trimestre, activité scientifique et données cliniques à venir

Imprimer PDF

Écrit par Didier Poli | 15 Mai 2012

Activité R&D accrue avec la préparation du lancement de la Phase IIb

Communication et activité scientifique intense en vue du congrès de l'EAACI

L'AP-HP, partenaire de DBV, présentera lors d'un late breaking abstract : "Six mois d'immunothérapie épicutanée dans l'allergie à l'arachide : innocuité et efficacité"

Nouveau brevet accordé aux Etats-Unis: Viaskin® est désormais le...

Lire la suite... Ajouter un commentaire

Killing Two Birds With One Stone: One Fusion Protein Takes Out Multiple Autoimmune Targets

Imprimer PDF

Écrit par GlobalData | 14 Mai 2012

LONDON, UK (GlobalData), 14 May 2012 - Recently Compugen, Ltd., an Israel-based biopharmaceutical company with over 17 years of research experience, released animal model data from the company’s proprietary Protein Family Members Discovery Platform. This in-house, in silico bioinformatics system provides a predictive view of protein characteristics leading to gene and protein discovery...

Lire la suite... Ajouter un commentaire

Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure

Imprimer PDF

Écrit par Pluristem | 10 Mai 2012

IM Injections of PLX Cells Causing a Dramatic Recovery of Blood Forming Cells

HAIFA, ISRAEL, May 9, 2012 – Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE:PLTR) today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white...

Lire la suite... Ajouter un commentaire

Plus d'articles...

Information

Annuaires

Vitrines Sociétés

Voir toutes les vitrines